Peer-reviewedCC BY-NC-ND 4.0NPJ Precision Oncology
Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology
11 affiliations
- 1Dana-Farber Cancer Institute, Boston, MA USA
- 2Indiana University School of Medicine, Indianapolis, IN USA
- 3Stanford University, Palo Alto, CA USA
- 4The University of Chicago Medicine, Chicago, IL USA
- 5MD Anderson Cancer Center, Houston, TX USA
- 6University of California, Davis, Davis, CA USA
- 7Gustave Roussy, Villejuif, France
- 8University of California, Los Angeles, Santa Monica, CA USA
- 9Mayo Clinic Rochester, Rochester, MN USA
- 10Mass General Brigham Cancer Institute at MGH Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Boston, MA USA
- 11Georgetown University, Washington, DC USA
Abstract
Thymic epithelial tumors (TETs) are rare and diverse cancers with distinctive immune features, limited prospective evidence, and few systemic options. Their association with autoimmunity, especially thymomas, complicates treatment decisions. This review examines molecular profiling and predictive biomarkers in TET and explores new treatment strategies. We highlight priorities for future trials, global registries, and real-world data to expand access to expert, multidisciplinary care, charting a path toward precision-guided, combination-based treatments.
Related
- From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD
- Shared mechanisms and therapeutic horizons: exploring the potential interplay between benign prostatic hyperplasia/lower urinary tract symptoms and Alzheimer’s disease
- Infantile-Onset Pompe Disease: Current Therapeutic Landscape, Clinical Challenges, and Future Horizons.
- Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC–ICI combinations, and global real-world integration
- Decoding the endothelin-1 network: molecular drivers of ovarian cancer malignancy and new therapeutic horizons
BibTeX
@article{marks2026redefining,
title = {{Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology}},
author = {Jennifer A. Marks and Rohan Maniar and Kavitha J. Ramchandran and Erica Pietroluongo and Mehmet Altan and Surbhi Singhal and Mihaela Aldea and Jonathan W. Goldman and Jonathan W. Reiss and Heather Wakelee and Patrick J. Loehrer and Marina Chiara Garassino and Anja C. Roden and Jordi Remon and Christopher S. Nabel and Chul Kim},
journal = {NPJ Precision Oncology},
year = {2026},
month = jun,
doi = {10.1038/s41698-026-01574-z},
url = {https://doi.org/10.1038/s41698-026-01574-z},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology
AU - Jennifer A. Marks
AU - Rohan Maniar
AU - Kavitha J. Ramchandran
AU - Erica Pietroluongo
AU - Mehmet Altan
AU - Surbhi Singhal
AU - Mihaela Aldea
AU - Jonathan W. Goldman
AU - Jonathan W. Reiss
AU - Heather Wakelee
AU - Patrick J. Loehrer
AU - Marina Chiara Garassino
AU - Anja C. Roden
AU - Jordi Remon
AU - Christopher S. Nabel
AU - Chul Kim
PY - 2026
DA - 2026/06/26
JO - NPJ Precision Oncology
DO - 10.1038/s41698-026-01574-z
UR - https://doi.org/10.1038/s41698-026-01574-z
AB - Thymic epithelial tumors (TETs) are rare and diverse cancers with distinctive immune features, limited prospective evidence, and few systemic options. Their association with autoimmunity, especially thymomas, complicates treatment decisions. This review examines molecular profiling and predictive biomarkers in TET and explores new treatment strategies. We highlight priorities for future trials, global registries, and real-world data to expand access to expert, multidisciplinary care, charting a path toward precision-guided, combination-based treatments.
SN - 2397-768X
ER -